Letter: Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Liver Cancer-Results From the Global Burden of Disease Study 2021. Authors' Reply.
作者信息
Danpanichkul Pojsakorn, Kim Donghee, Kalligeros Markos, Singal Amit G, Yang Ju Dong, Wijarnpreecha Karn
机构信息
Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
出版信息
Aliment Pharmacol Ther. 2025 Mar;61(6):1080-1081. doi: 10.1111/apt.18520. Epub 2025 Jan 23.
Abstract
摘要
相似文献
1
Letter: Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Liver Cancer-Results From the Global Burden of Disease Study 2021. Authors' Reply.信函：代谢功能障碍相关脂肪性肝病相关肝癌的全球负担——来自《2021年全球疾病负担研究》的结果。作者回复
Aliment Pharmacol Ther. 2025 Mar;61(6):1080-1081. doi: 10.1111/apt.18520. Epub 2025 Jan 23.
2
Liver cancer in 2021: Global Burden of Disease study.2021年肝癌：全球疾病负担研究
J Hepatol. 2025 May;82(5):851-860. doi: 10.1016/j.jhep.2024.10.031. Epub 2024 Oct 30.
3
Letter: Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Liver Cancer-Results From the Global Burden of Disease Study 2021.
Aliment Pharmacol Ther. 2025 Mar;61(6):1077-1079. doi: 10.1111/apt.18510. Epub 2025 Jan 23.
4
Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.监测代谢功能障碍相关脂肪性肝病的疾病进展
Aliment Pharmacol Ther. 2024 Jun;59 Suppl 1(Suppl 1):S41-S51. doi: 10.1111/apt.17752.
5
Letter: Metabolic Dysfunction-Associated Steatotic Liver Disease in Primary Biliary Cholangitis-Friend, Foe or Red Herring? Authors' Reply.
Aliment Pharmacol Ther. 2024 Dec;60(11-12):1643-1644. doi: 10.1111/apt.18332. Epub 2024 Oct 9.
6
Letter: Comparing the Efficacy of Adjuvant PD-1 Inhibitor After Curative Resection for Metabolic Dysfunction-Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies-Authors' Reply.
Aliment Pharmacol Ther. 2025 Jun;61(11):1841-1842. doi: 10.1111/apt.70126. Epub 2025 Apr 4.
7
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective.应对代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）日益加重的全球负担：从患病率上升到支付方视角
Aliment Pharmacol Ther. 2025 May;61(9):1467-1478. doi: 10.1111/apt.70020. Epub 2025 Feb 18.
8
Global Trends and Inequalities of Liver Complications Related to Metabolic Dysfunction-Associated Steatotic Liver Disease: An Analysis From 1990 to 2021.与代谢功能障碍相关脂肪性肝病相关肝脏并发症的全球趋势及不平等现象：1990年至2021年的分析
Liver Int. 2025 Apr;45(4):e16120. doi: 10.1111/liv.16120. Epub 2024 Oct 10.
9
Epidemiology of gastrointestinal cancers: a systematic analysis from the Global Burden of Disease Study 2021.胃肠道癌症流行病学：来自《2021年全球疾病负担研究》的系统分析
Gut. 2024 Dec 10;74(1):26-34. doi: 10.1136/gutjnl-2024-333227.
10
The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease.酒精摄入与代谢功能障碍相关脂肪性肝病和代谢功能障碍及酒精相关肝病中与心血管代谢因素和肝纤维化的关联。
Aliment Pharmacol Ther. 2024 Dec;60(11-12):1587-1598. doi: 10.1111/apt.18280. Epub 2024 Sep 23.
本文引用的文献
1
Letter: Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Liver Cancer-Results From the Global Burden of Disease Study 2021.
Aliment Pharmacol Ther. 2025 Mar;61(6):1077-1079. doi: 10.1111/apt.18510. Epub 2025 Jan 23.
2
Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021.2000 - 2021年酒精性肝病、肝癌及酒精使用障碍的全球流行病学
Clin Mol Hepatol. 2025 Apr;31(2):525-547. doi: 10.3350/cmh.2024.0835. Epub 2025 Jan 9.
3
Alcohol-Related Liver Disease, Followed by Metabolic Dysfunction-Associated Steatotic Liver Disease, Emerges as the Fastest-Growing Aetiologies for Primary Liver Cancer in the United States.酒精性肝病，其次是代谢功能障碍相关脂肪性肝病，成为美国原发性肝癌增长最快的病因。
Aliment Pharmacol Ther. 2025 Mar;61(6):959-970. doi: 10.1111/apt.18473. Epub 2025 Jan 5.
4
Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021.与MASH相关的肝癌全球趋势：来自《2021年全球疾病负担》的系统分析
Clin Gastroenterol Hepatol. 2025 Jul;23(8):1346-1355. doi: 10.1016/j.cgh.2024.10.026. Epub 2024 Dec 16.
5
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease.代谢功能障碍与酒精性肝病（MetALD）：酒精性肝病专家小组立场声明
J Hepatol. 2025 Apr;82(4):744-756. doi: 10.1016/j.jhep.2024.11.028. Epub 2024 Nov 27.
6
Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria.根据2023年标准，美国不同种族或族裔的脂肪变性患病率差异。
Commun Med (Lond). 2024 Oct 29;4(1):219. doi: 10.1038/s43856-024-00649-x.
7
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.全球 204 个国家和地区及 811 个亚级行政区 1990 年至 2021 年 288 种死因及预期寿命的归因分析：全球疾病负担研究 2021 系统分析。
Lancet. 2024 May 18;403(10440):2100-2132. doi: 10.1016/S0140-6736(24)00367-2. Epub 2024 Apr 3.
8
Global and regional burden of alcohol-associated liver disease and alcohol use disorder in the elderly.老年人酒精性肝病和酒精使用障碍的全球及区域负担
JHEP Rep. 2024 Jan 26;6(4):101020. doi: 10.1016/j.jhepr.2024.101020. eCollection 2024 Apr.
9
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
10
Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder.酒精相关性肝病：酒精使用障碍的综合管理。
Clin Gastroenterol Hepatol. 2023 Jul;21(8):2124-2134. doi: 10.1016/j.cgh.2023.02.017. Epub 2023 Feb 27.
Zotero 插件